医学
耐火材料(行星科学)
挽救疗法
内科学
再生障碍性贫血
胃肠病学
外科
化疗
骨髓
物理
天体生物学
作者
Tatsuhiro Sakamoto,Naoshi Obara,Yumiko Maruyama,Takayasu Kato,Naoki Kurita,Keiichiro Hattori,Yasuhito Suehara,Hidekazu Nishikii,Yasuhisa Yokoyama,Mamiko Sakata‐Yanagimoto,Kensuke Usuki,Shigeru Chiba
摘要
Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporin A is the standard treatment for aplastic anemia (AA). However, the efficacy of repeated IST with rabbit ATG (rATG) as salvage therapy remains unclear in patients with relapsed or refractory AA.We retrospectively evaluated the efficacy and safety of IST2 with rATG (IST2-rATG) in 19 consecutive patients with relapsed or refractory AA who received first-line IST with rATG in two centers between 2009 and 2020.The overall 6-month response rate of the patients was 58%. The response rates were similar between patients with relapsed and refractory AA. The presence of glycophosphatidylinositol-deficient blood cells was associated with a better response to IST2-rATG. Despite retreatment with the same rATG, serum disease and severe allergic reactions were not observed.IST2-rATG is effective and safe for the treatment of adult patients with relapsed and refractory AA after receiving first-line IST with rATG.
科研通智能强力驱动
Strongly Powered by AbleSci AI